Imugene has in-licenced a pipeline of B-cell vaccines that complements and advances its in-house programme. The deal has brought forward significant value-creation opportunities while maintaining Imugene’s focus on B-cell vaccine technologies. It accelerates the key PD-1 and PD-1/HER2 combo programmes by two years compared to its original pipeline. The company is well funded to accelerate key clinical studies for the newly combined pipeline. Our valuation is A$147m or 4.1 cents per shar
16 Aug 2018
Imugene - Checkpoint inhibitor vaccine programme accelerated
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Imugene - Checkpoint inhibitor vaccine programme accelerated
Imugene Ltd (IMU:ASX) | 0 0 -4.6% | Mkt Cap: 60.0m
- Published:
16 Aug 2018 -
Author:
Dr Dennis Hulme -
Pages:
17
Imugene has in-licenced a pipeline of B-cell vaccines that complements and advances its in-house programme. The deal has brought forward significant value-creation opportunities while maintaining Imugene’s focus on B-cell vaccine technologies. It accelerates the key PD-1 and PD-1/HER2 combo programmes by two years compared to its original pipeline. The company is well funded to accelerate key clinical studies for the newly combined pipeline. Our valuation is A$147m or 4.1 cents per shar